Hypercholesterolemia and dyslipidemia

Abstract

Disorders of cholesterol and lipoprotein metabolism are at the heart of atherosclerosis and coronary artery disease (CAD). CAD, however, is a metabolic disorder that involves a complex interaction between genetic susceptibility and environmental conditions. Despite considerable success in the treatment of hypercholesterolemia, atherosclerosis remains the leading cause of death in most Western countries. Although cholesterol-lowering trials have revealed a 25% to 30% reduction in clinical events, most patients continue to have events even when treated successfully with cholesterol-lowering medications (Fig. 1). This less-than-optimal result is partly because atherosclerosis is a multifactorial disease. Although disorders of lipoprotein metabolism are found in more than 80% of patients with CAD, these disorders are very heterogeneous, and single-drug therapy aimed at one disorder should not be expected to improve the disease status in most patients. Metabolic treatment still requires identification and treatment of patients with high cholesterol levels, but the focus has shifted to identifying high-risk patients in groups previously thought to be low risk, or to identifying disorders coexistent with high cholesterol levels that are not corrected by standard cholesterol-lowering medications (Table 1). The ability to detect high-risk CAD traits, which are often inherited, and to predict response to treatment has substantially improved in the past few years. These improvements allow identification of metabolic subgroups of patients, which can alter risk prediction and response to specific treatments. Sophisticated laboratory methods permit physicians to apply this knowledge to patient care and to enter a new era of CAD risk factor detection and treatment. These advances allow for a more scientific approach than did the previously standard epidemiologic risk factors and routine blood lipid profiles. The current state-of-the-art method of diagnosing and treating lipoprotein disorders has progressed beyond the standard "lipid profile," which includes total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol along with fasting triglyceride levels. Incorporating aspects of the atherogenic lipid profile (ALP), LDL subclass distribution, HDL subclass distribution, apo E isoforms, and lipoprotein (a) provides the interested clinician with the tools to create a more detailed and accurate diagnosis of lipoprotein disorders. Sophisticated laboratory tests are available to clinicians through technology transfer programs, as exemplified by the Lawrence Berkeley National Laboratory/Berkeley HeartLab collaboration, and allow clinicians access to research-quality laboratory tools. This has significant clinical relevance because the presence of these disorders guides treatment specific to the disorder(s). Appropriate treatment is more beneficial in subgroups exhibiting the disorder that the therapy is most likely to correct. A single drug or lifestyle therapy is no longer appropriate for all patients. The tr...

The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review

“…Disorders of cholesterol and lipoprotein metabolism are a well-known risk factor for atherosclerosis and consequently, a risk factor for CAD and HF as well [103]. In regard to the pathogenesis of atherosclerosis, conditions such as hypercholesterolemia are considered to play a large role [103].…”

“…Disorders of cholesterol and lipoprotein metabolism are a well-known risk factor for atherosclerosis and consequently, a risk factor for CAD and HF as well [103]. In regard to the pathogenesis of atherosclerosis, conditions such as hypercholesterolemia are considered to play a large role [103]. To elaborate, LDL exposed to the macrophages of an atherosclerotic lesion get oxidized, this oxidized LDL (LDL-ox) is then able to injure endothelial cells, aiding in the progression of atherosclerotic lesions [103].…”

Small LDL and Its Clinical Importance as a New CAD Risk Factor: A Female Case Study

“…A secondary LDL peak in the large region at 264.6 Å can be noted and indicates a proportion of her LDL particles are in the larger, less atherogenic region. Conversion of small dense LDL to larger buoyant LDL is best achieved with therapies that tend to lower triglycerides such as weight loss, restriction of simple sugars, and the use of nicotinic acid or fibric acid derivatives 42 …”

“…Pharmacologic treatment involves medications that tend to reduce triglycerides, such as nicotinic acid and the fibric acid derivatives 40,41 . Many medications have a differential response based on LDL subclass distribution 42 …”

Apolipoprotein A-V gene therapy for disease prevention / treatment:a critical analysis

“…While the TG content of plaque is far less prominent, evidence suggests that, in cells located in and around plaque deposits, TG-rich lipoproteins induce inflammation and related atherogenic processes [ 21 - 23 ] . Elevated TG also corre­lates with the formation of small dense LDL, lipoprotein particles that are positively associated with CHD risk and inflammation [ 24 ] . Given the very low concentration of apoA-V in plasma under normal circumstances, any decrease will likely impact lipoprotein-associated TG hydrolysis by LPL, thereby interfering with TG-rich lipo­protein clearance.…”